@article {46742,
	title = {Biosensors: frontiers in rapid detection of COVID-19},
	journal = {3 Biotech},
	volume = {10},
	year = {2020},
	month = {AUG},
	pages = {385},
	type = {Review},
	abstract = {<p>The rapid community-spread of novel human coronavirus 2019 (nCOVID19 or SARS-Cov2) and morbidity statistics has put forth an unprecedented urge for rapid diagnostics for quick and sensitive detection followed by contact tracing and containment strategies, especially when no vaccine or therapeutics are known. Currently, quantitative real-time polymerase chain reaction (qRT-PCR) is being used widely to detect COVID-19 from various types of biological specimens, which is time-consuming, labor-intensive and may not be rapidly deployable in remote or resource-limited settings. This might lead to hindrance in acquiring realistic data of infectivity and community spread of SARS-CoV-2 in the population. This review summarizes the existing status of current diagnostic methods, their possible limitations, and the advantages of biosensor-based diagnostics over the conventional ones for the detection of SARS-Cov-2. Novel biosensors used to detect RNA-viruses include CRISPR-Cas9 based paper strip, nucleic-acid based, aptamer-based, antigen-Au/Ag nanoparticles-based electrochemical biosensor, optical biosensor, and Surface Plasmon Resonance. These could be effective tools for rapid, authentic, portable, and more promising diagnosis in the current pandemic that has affected the world economies and humanity. Present challenges and future perspectives of developing robust biosensors devices for rapid, scalable, and sensitive detection and management of COVID-19 are presented in light of the test-test-test theme of the World Health Organization (WHO).</p>
},
	keywords = {Biosensors, COVID-19, Rapid detection, SARS-CoV-2},
	issn = {2190-572X},
	doi = {10.1007/s13205-020-02369-0},
	author = {Samson, Rachel and Navale, Govinda R. and Dharne, Mahesh S.}
}
@article {47624,
	title = {COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis},
	journal = {3 Biotech},
	volume = {12},
	year = {2022},
	month = {JAN},
	pages = {6},
	type = {Review},
	abstract = {The post-coronavirus disease (COVID-19) mucormycosis is a deadly addition to the pandemic spectrum. Although it{\textquoteright}s a rare, aggressive, and opportunistic disease, the associated morbidity and mortality are significant. The complex interplay of factors aggravating CAM is uncontrolled diabetes, irrational and excessive use of antibiotics, steroids, and an impaired immune system. Recently, India has been witnessing a rapid surge in the cases of coronavirus disease-associated mucormycosis (CAM), since the second wave of COVID-19. The devastating and lethal implications of CAM had now become a matter of global attention. A delayed diagnosis is often associated with a poor prognosis. Therefore, the rapid and early diagnosis of infection would be life-saving. Prevention and effective management of mucormycosis depend upon its early and accurate diagnosis followed by a multimodal therapeutic approach. The current review summarizes an array of detection methods and highlights certain evolving technologies for early and rapid diagnosis of CAM. Furthermore, several potential management strategies have also been discussed, which would aid in tackling the neglected yet fatal crisis of mucormycosis associated with COVID-19.},
	keywords = {Biosensors, COVID-19, Diagnostics, Mucormycosis, Probiotics},
	issn = {2190-572X},
	doi = {10.1007/s13205-021-03080-4},
	author = {Samson, Rachel and Dharne, Mahesh}
}
